Downregulation of amplified in breast cancer 1 contributes to the anti-tumor effects of sorafenib on human hepatocellular carcinoma

Multi-kinase inhibitor sorafenib represents a major breakthrough in the therapy of advanced hepatocellular carcinoma (HCC). Amplified in breast cancer 1 (AIB1) is frequently overexpressed in human HCC tissues and promotes HCC progression. In this study, we investigated the effects of sorafenib on AI...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ming, Wang, Wei, Dan, Yuzhen, Tong, Zhangwei, Chen, Wenbo, Qin, Liping, Liu, Kun, Li, Wengang, Mo, Pingli, Yu, Chundong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045420/
https://www.ncbi.nlm.nih.gov/pubmed/27105488
http://dx.doi.org/10.18632/oncotarget.8812

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045420/
https://www.ncbi.nlm.nih.gov/pubmed/27105488
http://dx.doi.org/10.18632/oncotarget.8812

Ejemplares similares